Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Donor-derived CAR-T Cells in Relapsed or Refractory AML
NCT04766840Phase 1Unknown
- Sponsor
- Immunochina Pharmaceuticals
- Start
- Mar 2021
- Primary completion
- Jun 2023
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IM73 CAR-T cells in acute myeloid leukemia (AML), sponsored by Immunochina Pharmaceuticals. Primary endpoint: Dose limiting toxicity at 28 days. Status: unknown.
02
Drugs
IM73 CAR-T cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04766840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04766840.